每年專案
個人檔案
學歷
- 2018 國立陽明大學臨床醫學研究所博士
- 2003 國防醫學院醫學系學士
經歷
- 衛生福利部雙和醫院婦產部主任
- 衛生福利部雙和醫院婦產部婦科主任
- 衛生福利部雙和醫院婦產部婦產科主治醫師
- 2023.02- 臺北醫學大學醫學系婦產學科副教授
- 臺北醫學大學醫學系婦產學科助理教授
- 2012.05-2019.03 臺北榮總醫院婦產部主治醫師
指紋
查看啟用 Kuo-Chang Wen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
-
研發新的DNA甲基化生物標誌以提高自我採檢MPap的性能(MPap 2.0)(2/2)
Wen, K.-C. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
研發新的DNA甲基化生物標誌以提高自我採檢MPap的性能(MPap 2.0)(1/2)
Wen, K.-C. (PI)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
-
The expression of BHLHE22 in endometrial carcinoma: Associations with mismatch repair protein expression status, tumor-infiltrating immune cells, programmed death-ligand 1 and clinical outcomes
Chen, L. Y., Chen, H. Y., Lai, H. C., Lin, S. F., Wen, K. C., Darmawi & Liew, P. L., 2025, 於: Taiwanese Journal of Obstetrics and Gynecology. 64, 1, p. 110-119 10 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 引文 斯高帕斯（Scopus） -
Active DNA Demethylase, TET1, Increases Oxidative Phosphorylation and Sensitizes Ovarian Cancer Stem Cells to Mitochondrial Complex I Inhibitor
Chen, L. Y., Shen, Y. A., Chu, L. H., Su, P. H., Wang, H. C., Weng, Y. C., Lin, S. F., Wen, K. C., Liew, P. L. & Lai, H. C., 6月 2024, 於: Antioxidants. 13, 6, 735.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
Correction to: In vitro drug testing using patient-derived ovarian cancer organoids (Journal of Ovarian Research, (2024), 17, 1, (194), 10.1186/s13048-024-01520-2)
Chen, L. Y., Chou, Y. T., Liew, P. L., Chu, L. H., Wen, K. C., Lin, S. F., Weng, Y. C., Wang, H. C., Su, P. H. & Lai, H. C., 12月 2024, 於: Journal of Ovarian Research. 17, 1, 243.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
In vitro drug testing using patient-derived ovarian cancer organoids
Chen, L. Y., Chou, Y. T., Liew, P. L., Chu, L. H., Wen, K. C., Lin, S. F., Weng, Y. C., Wang, H. C., Su, P. H. & Lai, H. C., 12月 2024, 於: Journal of Ovarian Research. 17, 1, 194.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取2 引文 斯高帕斯（Scopus） -
Periureteral liposarcoma causes of hydroureter and hydronephrosis: An unpredictable diagnosis
Lin, T. E., Wen, K. C., Lai, H. C. & Chu, L. H., 1月 2023, 於: Gynecology and Minimally Invasive Therapy. 12, 1, p. 51-54 4 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取
資料集
-
Additional file 2 of Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer
Huang, C.-Y. F. (Contributor), Chou, P.-C. (Contributor), Wen, K.-C. (Creator), Lee, M.-H. (Contributor), Lin, J.-H. (Contributor), Sung, P.-L. (Contributor), Yeung, S.-C. J. (Contributor) & Wu, A. T. H. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12845525.v1, https://doi.org/10.6084%2Fm9.figshare.12845525.v1
資料集: Dataset
-
Additional file 3 of Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer
Huang, C.-Y. F. (Contributor), Lin, J.-H. (Contributor), Wu, A. T. H. (Creator), Sung, P.-L. (Contributor), Lee, M.-H. (Contributor), Yeung, S.-C. J. (Contributor), Chou, P.-C. (Contributor) & Wen, K.-C. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.12845528.v1, https://doi.org/10.6084%2Fm9.figshare.12845528.v1
資料集: Dataset
-
Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer
Lee, M.-H. (Contributor), Yeung, S.-C. J. (Contributor), Chou, P.-C. (Contributor), Lin, J.-H. (Contributor), Wen, K.-C. (Creator), Huang, C.-Y. F. (Contributor), Sung, P.-L. (Contributor) & Wu, A. T. H. (Creator), Figshare, 2020
DOI: 10.6084/m9.figshare.c.5099513.v1, https://doi.org/10.6084%2Fm9.figshare.c.5099513.v1
資料集: Dataset
-
Additional file 1 of Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer
Chou, P.-C. (Contributor), Wu, A. T. H. (Creator), Sung, P.-L. (Contributor), Huang, C.-Y. F. (Contributor), Lin, J.-H. (Contributor), Wen, K.-C. (Creator), Yeung, S.-C. J. (Contributor) & Lee, M.-H. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.12845522.v1, https://doi.org/10.6084%2Fm9.figshare.12845522.v1
資料集: Dataset
-
Additional file 1 of Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y.-C. (Contributor), Wen, K.-C. (Creator), Sung, P.-L. (Contributor), Chou, Y.-T. (Creator), Liew, P.-L. (Contributor), Chen, L.-Y. (Contributor), Huang, R.-L. (Creator), Lai, H.-C. (Contributor) & Chang, L.-T. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.13352142.v1, https://springernature.figshare.com/articles/figure/Additional_file_1_of_Complete_remission_of_heavily_treated_ovarian_clear_cell_carcinoma_with_ARID1A_mutations_after_pembrolizumab_and_bevacizumab_combination_therapy_a_case_report/13352142/1
資料集: Dataset